Kilic-Kurt Zühal, Bakar-Ates Filiz, Karakas Bahriye, Kütük Özgür
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Ankara University, Tandogan, Ankara, Turkey.
Department of Biochemistry, Faculty of Pharmacy, Ankara University, Tandogan, Ankara, Turkey.
Anticancer Agents Med Chem. 2018;18(9):1303-1312. doi: 10.2174/1871520618666180605082026.
Pyrrolo[2,3-d]pyrimidines have been recently reported to have anticancer activities through inhibition of different targets such as, Epidermal Growth Factor Receptor (EGFR) tyrosine kinase, Janus Kinase (JAK), mitotic checkpoint protein kinase (Mps1), carbonic anhydrase, MDM-2. On the other hand, aryl urea moieties which are found in some tyrosine kinase inhibitors such as Sorafenib and Linifanib have aroused recent attention as responsible for anticancer activities. The aims of this paper are to synthesize pyrrolo[ 2,3-d]pyrimidine derivatives containing urea moiety and evaluate their anti-cancer activity against human lung cancer cell line (A549), prostate cancer cell line (PC3), human colon cancer cell line (SW480) and human breast cancer cell line (MCF-7).
A series of new pyrrolo[2,3-d]pyrimidines containing urea moieties have been synthesized as Scheme 1. In vitro cytotoxicity of target compounds were evaluated against, SW480, PC3, A549 and MCF-7 human cancer cell lines using a MTT assay. In order to evaluate the mechanism of cytotoxic activity of compounds 9e, 10a and 10b, having the best cytotoxic activity, Annexin V binding assay, cell cycle analysis and western blot analysis were performed.
Among the target compounds, 10a (IC50 = 0.19 µM) was found to be the most potent derivative against PC3 cells. Compound 10b and 9e showed the strong cytotoxic activity against MCF-7 and A549 cells with IC50 value of 1.66 µM and 4.55 µM, respectively. Flow cytometry data suggest that the cytotoxic activity of the compounds on cancer cells might be mediated by apoptosis revealing a significant increase in the percentage of late apoptotic cells and causing a cell cycle arrest at different stages. Western blot analysis of apoptosis marker demonstrated that these compounds induce apoptosis through the intrinsic pathway.
Compound 9e displayed the strongest cytotoxicity against A549 cancer cell line, and induced late apoptosis in A549, as confirmed by cell cycle arrest in G0/G1 phase. In addition, compound 9e reduced expression of the anti-apoptotic protein Bcl-2 and enhanced expression of the pro-apoptotic protein Bax, besides increased caspase-9 and caspase-3, as well as cleavage of PARP levels. These results suggest that compound 9e showed a cytotoxic effect in A549 cells through activation of the mitochondrial apoptotic pathway. Further studies will be undertaken in our laboratory to improve cytotoxic activity of compound 9e and to identify the biological targets of 9e which are responsible for anticancer activity.
最近有报道称吡咯并[2,3 - d]嘧啶通过抑制不同靶点具有抗癌活性,这些靶点包括表皮生长因子受体(EGFR)酪氨酸激酶、Janus激酶(JAK)、有丝分裂检查点蛋白激酶(Mps1)、碳酸酐酶、MDM - 2。另一方面,在一些酪氨酸激酶抑制剂如索拉非尼和林尼伐尼中发现的芳基脲部分,因其抗癌活性而引起了近期的关注。本文的目的是合成含有脲部分的吡咯并[2,3 - d]嘧啶衍生物,并评估它们对人肺癌细胞系(A549)、前列腺癌细胞系(PC3)、人结肠癌细胞系(SW480)和人乳腺癌细胞系(MCF - 7)的抗癌活性。
按照方案1合成了一系列含有脲部分的新型吡咯并[2,3 - d]嘧啶。使用MTT法评估目标化合物对SW480、PC3、A549和MCF - 7人癌细胞系的体外细胞毒性。为了评估具有最佳细胞毒性活性的化合物9e、10a和10b的细胞毒性作用机制,进行了膜联蛋白V结合试验、细胞周期分析和蛋白质印迹分析。
在目标化合物中,发现10a(IC50 = 0.19 μM)是对PC3细胞最有效的衍生物。化合物10b和9e对MCF - 7和A549细胞显示出较强的细胞毒性活性,IC50值分别为1.66 μM和4.55 μM。流式细胞术数据表明,这些化合物对癌细胞的细胞毒性活性可能是由凋亡介导的,晚期凋亡细胞百分比显著增加,并导致细胞周期在不同阶段停滞。凋亡标志物的蛋白质印迹分析表明,这些化合物通过内在途径诱导凋亡。
化合物9e对A549癌细胞系表现出最强的细胞毒性,并诱导A549细胞晚期凋亡,这通过G0/G1期细胞周期停滞得到证实。此外,化合物9e降低了抗凋亡蛋白Bcl - 2的表达,增强了促凋亡蛋白Bax的表达,同时增加了caspase - 9和caspase - 3以及PARP水平的裂解。这些结果表明,化合物9e通过激活线粒体凋亡途径在A549细胞中显示出细胞毒性作用。我们实验室将进一步开展研究,以提高化合物9e的细胞毒性活性,并确定负责抗癌活性的9e的生物学靶点。